Paradigm Biocapital Advisors LP

Q3 2022 13F-HR Holdings

Location
New York, NY
Holdings as of
9/30/2022
Date filed
11/14/2022
Form type
13F-HR
Num holdings
28
Total value ($000)
$750,139
Net value change ($000)
+248,609 (49.6%)
New positions
9
Sold out positions
5
Turnover %
31.4%
Sector allocation + QoQ delta (equities-only)
Prev filing: 8/15/2022 Next filing: 2/14/2023 SEC filing

Snapshot: Change Analysis

Compared to Q2 2022
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
BIIB 41,280 NEW
Global Blood Therapeutics, Inc. 33,891 73.4%
AKRO 28,373 NEW
AXSM 23,206 NEW
Horizon Therapeutics Public Ltd Co 21,748 NEW
VRDN 18,442 122.0%
Mirati Therapeutics, Inc. 15,087 34.1%
PRTA 14,298 NEW
IMCR 11,387 45.7%
ASND 11,181 27.8%
Top Reduces (Value $000, Stocks/ETFs)
Sierra Oncology, Inc. -44,064 -100.0%
LEGN -9,898 -18.4%
ARVN -9,153 -42.0%
UTHR -8,994 -23.4%
ENTA -7,006 -100.0%
Gracell Biotechnologies Inc. -4,309 -100.0%
LQDA -3,710 -100.0%
ARGX -1,772 -5.3%
CCCC -552 -100.0%
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000): 40,050 (5.3% of total reported value)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type